Ambient Scribes
R

Reteta

Ambient scribe and coding platform launched October 2024 by Visionet Ventures out of Cranbury, New Jersey, after roughly two years of development and backed by $2 million in seed funding. The company is small, in the range of one to ten people.

It ships as two products. Reteta sKribe captures ambient audio without dictation and generates SOAP notes, after visit summaries, referral letters to other specialties and pre charting across more than 15 specialties. Reteta Bcoder handles the coding side, with real time ICD-10 and CPT suggestions surfacing during the encounter rather than afterwards, alongside clinical documentation improvement prompts that identify gaps while the clinician is still documenting. Integration is described as bolting onto any EHR through secure APIs and HL7 or FHIR, writing notes, coding and summaries back into Epic, Cerner, athenahealth and eClinicalWorks among others.

Two capabilities are uncommon. The positioning is built on explainability: the vendor states that every entry in a generated note can be traced back to the point in the conversation it came from, which turns verification into something a clinician can perform in seconds. And the after visit summary is generated to the patient's own health literacy level and preferred language, including education materials, treatment regimens and caregiver notes, which treats the summary as a comprehension problem rather than a formatting one.

The vendor also publishes a speech accuracy figure across diverse accents and dialects, reporting 86 percent. Two things about it should be read together. It is a single aggregate across a varied sample rather than a breakdown by accent, so it does not establish how performance differs between groups. And it is one of at least four accuracy figures the company publishes that cannot all describe the same thing, none of which carries a method or a denominator, with this one appearing in a blog post comparing the product against a named competitor rather than in technical documentation.

AI Health Index verifiedSeptember 14, 2026
Compare Reteta with other vendors
Founded
2024
Headquarters
Cranbury, New Jersey
Website
www.reteta.com
Categories
ambient-scribes
Assessment

Capability Axes

An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read

AI Capability
AA on AI CentralityThe artificial intelligence is the product. Remove the model and there is nothing left to sell.
Vendor Published

Ambient capture, note generation, pre charting, after visit summaries, referral letters and the coding output in Bcoder are all model produced. No human scribe tier and no services layer. The company is a product company launched out of a venture studio rather than an existing services business adding AI, and both products are sold as the thing itself rather than as a feature of a platform.

BB on Autonomy and Oversight ModelThe oversight structure is described and one part is missing, commonly the threshold at which the system stops or what happens after it is wrong.
Vendor Published

The review gate is described plainly, with clinicians reviewing and signing generated notes before they enter the record, and the explainability design is a real oversight mechanism rather than a slogan. If a clinician can trace any sentence in a note back to the moment in the conversation it came from, verification becomes something they can perform in seconds rather than a re-reading of the whole note against memory. That is the difference between a review step that is checkable and one that depends on recall.

Three things weaken it.

The traceability claim is asserted without a demonstration, an error rate or any description of how the trace is presented at review.

Coding suggestions and documentation-improvement prompts surface in real time during the encounter, with no published confidence threshold and no described behavior when the system is uncertain. A prompt arriving during the consultation shapes what the clinician documents while they are documenting it, which is a stronger form of influence than a suggestion offered after the visit.

And the figure that 80 percent of notes are accepted without edits is presented as a benefit when it also describes how often the review step changes nothing. Turned around, it says four notes in five are signed as generated. Whether that reflects a good draft or a light review is exactly what an acceptance rate cannot distinguish on its own.

CC on Model and Technology TransparencyThe architecture is described in general terms with nothing identified. Proprietary is asserted rather than explained.
Vendor Published

Nothing is published about what is under the hood. No model or model family is named, no foundation model provider is identified, no architecture is described beyond natural language understanding as a category, no training data is characterized, and no versioning or update practice is published, so there is no way to know when the system changed or what changed with it.

One property is described rather than named, and it is a real one. The vendor states explainability as an architectural commitment: every entry in a generated note is said to trace back to the point in the conversation it came from. That describes a design behavior without identifying what implements it.

An accuracy figure is a performance disclosure rather than a statement about what produces the output, and the figures here compound the problem rather than relieving it. At least four are published that cannot all describe the same thing: a figure across diverse accents, a homepage figure using the unfalsifiable up-to construction, a proportion of notes accepted without edits, and a separate coding accuracy figure. None carries a method, a denominator or an evaluation design, and one of them sits in a blog post comparing the product with a named competitor, which is marketing rather than technical documentation. A vendor publishing four unreconciled numbers is publishing less information than one publishing a single number with a method.

DD on Model Supply Chain DisclosureNothing establishes who else sits between a patient record and an answer.
Vendor Published

Nothing identifies any party in the chain. No model or model family, no foundation model provider, no hosting arrangement and no subprocessor list is published. End-to-end encryption is stated for protected health information in transit and at rest, which protects content without naming who processes it.

One capability creates a content type that stands apart, because it is derived rather than captured, and the ordinary analysis of a scribe does not reach it.

The after-visit summary generation reads the patient's language preference and infers their health literacy level in order to adapt what it produces. An inferred health literacy level is an attribute the system assigns to a person. It did not come from the patient, the patient is unlikely to know it exists, and it is the kind of derived characteristic that can persist and travel further than the summary it was created for. If it is written to the record, it becomes part of the patient's chart; if it is retained for personalization, it becomes a profile.

The coding product raises the chain question a second time, since a real-time coding suggestion generated during an encounter is produced somewhere, from something, and neither is named.

Nothing published says which patient attributes the system derives, where they are stored, whether they are written to the record, whether the patient can see or contest them, or whether they are excluded from any model improvement process.

CC on Clinical and Operational EvidenceNamed customers, or vendor reported percentages with no method, denominator or reference standard. Scale of use is recorded here and is not treated as evidence of benefit.
Vendor Published

No study, controlled evaluation, third party assessment or named customer is published. Adoption is described only as hundreds of satisfied healthcare providers, with no organization named and no deployment count. Every performance figure is vendor stated without method: two hours saved per clinician per day, SOAP notes in under two minutes, burnout reduced by up to 75 percent, an 85 percent increase in claim approval, 70 percent coding productivity gain.

Presence on the Elion and AVIA marketplaces is not validation: the Elion profile is explicitly marked unclaimed, meaning it was generated by the directory rather than submitted and verified by the vendor.

CC on AI Safety and PHI StewardshipGeneral assurances of privacy and security that do not answer the questions artificial intelligence raises: what is retained, what reaches a model, and what happens to it there.
Vendor Published

End-to-end encryption is stated for protected health information, and the company describes safeguarding data in transit and at rest.

Nothing further is published. There is no audio retention schedule, no deletion commitment, no de-identification practice and no statement in either direction on whether customer content is used to train or improve models. Encryption without a retention answer is an ordinary position rather than a strong one: it describes how content is protected while it is held, and says nothing about how long it is held or what else is done with it.

The gap is wider here than for a scribe alone, because the platform holds more kinds of content. Encounter audio, generated notes, pre-charting drawn from the record before the visit, after-visit summaries and coding output all sit with the vendor, and they are unlikely to be governed identically.

One derived attribute stands apart. The after-visit summary generation reads the patient's language preference and infers their health literacy level in order to adapt what it produces. That is a characteristic the system assigns to a person rather than one the patient supplied, and nothing published says what attributes of this kind are derived, where they are stored, whether they are written to the record, or whether they are excluded from any model improvement process.

Regulatory and Compliance
BB on HIPAA and BAA PostureBusiness associate status is stated and supported by a substantive privacy document, with the agreement or its scope not fully published. For a vendor outside the United States, an equivalent regime documented to this depth grades here. A vendor whose product does not process protected health information grades here too when it says so plainly and explains the scope, with a service privacy document behind it: stating a position a buyer can rely on is the posture this axis grades, and the band above is closed to it because there is no agreement to publish.
Vendor Published

The certification claim is unconfirmed. A certification under a named third party health privacy compliance program has been attributed to the vendor, and it would name an assessing body that could be asked for evidence. The vendor's current product pages and its own launch announcement give only the general formulation: end-to-end encryption and a health privacy compliant framework, with compliance protocols described rather than attested. The named program does not appear.

A claim that cannot be found now is not the same as one the vendor never made, but it cannot be relied on either. Nothing published says whether any third party compliance certification is held, by which assessor, with what scope or from what date.

What is established is thinner. Compliance is claimed, encryption in transit and at rest is stated, and no business associate agreement terms, availability, scope or tier gating are published anywhere.

The integration surface sharpens the agreement question. This product writes notes, codes and summaries back into hospital record systems, so it handles protected health information for organizations whose own obligations flow down to it, and those organizations will require the agreement before anything is connected.

CC on Security Certifications and Trust CenterControls are described with an outside check behind them, such as independent penetration testing on a stated cadence, but no attestation against a recognized framework. A certification that tests the software security features rather than the vendor operations, such as federal health IT certification, is an outside check of this kind.
Vendor Published

No SOC 2 report of either type, no ISO 27001 certification, no penetration testing statement, no audit report and no trust center appears anywhere. The vendor describes end-to-end data protection, which is a claim about design rather than an examination of it.

One distinction is worth restating because it is the kind of item that inflates a compliance list. A health privacy rule compliance attestation is a different object from a security controls attestation. It speaks to a documented compliance program rather than to an independent examination of technical and organizational controls. Laws, regulators, conformity marks and control attestations are four different kinds of thing, and a list mixing them reads as more than it contains.

The absence matters in proportion to what the platform holds and who it sells to. This vendor integrates with major hospital record systems through interface standards and writes notes, codes and summaries back into them, so it holds encounter audio, generated documentation and coding output for organizations whose procurement functions expect an examined posture as a matter of routine. Selling into that buyer without one is a harder position than selling to a solo practice without one, and it is the first thing a health system security review will ask for.

None of this is a judgment that controls are absent; it describes what a counterparty can verify before contracting. For a company founded in 2024 with fewer than ten people, the absence is expected; the buyer profile is what makes it consequential.

CC on FDA and Regulatory StatusNo device claim is made and the product is scoped accordingly. Most administrative and operational products sit here and are not penalized for it, because this axis grades the appropriateness of the positioning rather than possession of a clearance.
Vendor Published

Ambient documentation needs no clearance, and none is claimed. No United States device pathway attaches to a note the clinician reviews and signs.

What governs is payment integrity, and this product sits at the sharp end of it. The platform pairs an ambient scribe with a dedicated coding product delivering real time coding suggestions. The vendor markets real time coding visibility as helping clinicians maximize reimbursement accuracy, describes compressing the clinical documentation improvement cycle from days to minutes by identifying documentation gaps during the encounter, and claims a large increase in claim approval.

The field has now published on precisely this, which makes the concern a documented pattern. A 2025 policy analysis in a peer reviewed digital medicine journal describes the business case for ambient scribes shifting from clinician wellbeing toward revenue capture through more intensive coding, and reports measured effects: an eleven percent rise in physician work relative value units and a fourteen percent increase in documented hierarchical condition category diagnoses per encounter at one health system, more high level evaluation and management visits billed at another, and an oncology study finding documented diagnoses per encounter rising from three to four point one.

That analysis names the question this vendor faces: whether better coding reflects better documentation of care actually delivered, or more intensive coding of the same care. Identifying gaps during the encounter rather than after the visit is the sharper version, because it shapes what the clinician documents while they are documenting it.

One thing counts in its favor. The vendor describes its scribe as explainable and its coding as traceable to the encounter. A suggestion a clinician can trace back to what was said is reviewable in a way an unexplained one is not, and that is the right direction for a product on this gradient.

CC on AI Governance and Bias DisclosureResponsible artificial intelligence is committed to in policy language with no evaluation behind it. Most of the index sits here.
Vendor Published

Mixed, and both halves matter.

The positives are real and unusual for a company of this size. The vendor publishes an accuracy figure for speech across diverse accents and dialects at 86 percent, and it is not a flattering number, which makes it more credible rather than less. Generating the after-visit summary to the patient's own health literacy level and preferred language is an accessibility design decision rather than a marketing line, and it addresses a failure mode most documentation products ignore. Explainability gives a clinician a route to challenge an output.

The figure is not a subgroup breakdown, and that distinction matters. A single aggregate percentage measured across a diverse sample tells a buyer that the system was tested on varied speech; it does not say how performance differs between one accent and another, which is the disclosure that would let a practice serving a particular population know whether the product works for them. No per-group figures, no method, no sample description and no model card accompany it.

Against that, the coding posture puts the product on the reimbursement gradient. Documentation improvement capabilities are described as identifying documentation gaps during the encounter rather than after the visit, compressing a cycle that normally takes days into minutes, and the outcome sold is an 85 percent increase in claim approval alongside claim ready notes. Prompting at the point of care shapes what the clinician documents while they are documenting it. The framing here sits at the defensive end, denial avoidance rather than maximizing intensity, which is the milder version of the pattern.

CC on AI Liability and RecourseMechanisms exist that let someone challenge an output, such as audit trails, source traceability or review before commit, with nothing standing behind the output and no route for the harmed party.
Vendor Published

The strongest point is traceability. Every entry in a generated note is stated to trace back to the point in the conversation it came from, which is a correction route available at the moment of review rather than a policy commitment. A clinician who can check a sentence against the words that produced it can challenge it in seconds.

The vendor also publishes an accuracy figure for speech across diverse accents at 86 percent, and it is not a flattering number. Publishing an unflattering figure at all is a form of accountability.

What is missing is a published error rate with its method and denominator. At least four accuracy claims are published that cannot all describe the same thing: the accent figure, a homepage figure using the unfalsifiable up-to construction, a proportion of notes accepted without edits, and a coding accuracy figure. No methodology, denominator or evaluation design accompanies any of them, and the accent figure sits in a blog post comparing the product with a named competitor rather than in technical documentation.

Nothing stands behind the output either. No warranty, indemnity or remediation commitment is published, and no route is described for a patient who finds an error.

Integration and Deployment
BB on EHR and Interoperability DepthNamed systems with read access or one directional writing, or standards support with named deployments behind it.
Vendor Published

Described as standards-based and bidirectional: secure interfaces over HL7 and FHIR, writing SOAP notes, coding and summaries back into the record, with Epic, Cerner, athenahealth and eClinicalWorks named, plus access to patient information and appointments from inside the platform. Naming a standard and naming systems is the right shape, and it goes beyond simple transfer, where a note is produced and moved by hand.

Two gaps remain.

The phrase bolts onto any EHR is a universality claim, and universal compatibility is usually a consequence of not integrating rather than of integrating well. The named list ends in and more, with no supported-systems page behind it and no per-system documentation, so nothing shows which connections are built and which are asserted.

And nothing is demonstrated. No customer is named on any specific system, no marketplace listing is cited, and no reference deployment is published, so the integrations are described rather than shown running.

The distinction that matters most in practice is what write-back actually produces. A note landing as discrete coded fields is a different product from one landing as a block of text in a free-text box, and the difference determines whether the coding output is usable downstream or has to be re-entered.

Nothing published shows whether write back lands as discrete coded fields or as a text blob, or which of the named systems are live today.

CC on Deployment Model and Data ResidencyA single hosted option with location implied rather than committed.
Vendor Published

Delivery is a cloud platform. No hosting region, no residency option, no subprocessor list and no on-premise path is published.

What is better established is the integration mechanism, and it matters because the route a scribe takes into the chart varies more than buyers expect. This product connects through secure interfaces and the standard health interoperability protocols, writing notes, codes and summaries back that way. That is a permissioned integration rather than browser manipulation or robotic process automation driving the record system as a user, so its actions carry their own identity and the record system's own access controls apply to them. Where a product operates under a clinician's credentials instead, the audit trail stops being a reliable record of who did what.

What remains unanswered is where the processing happens. Nothing establishes where transcription and note generation run, whether a third-party model service performs either, which provider that would be, or what it retains. The coding product raises the same question separately, since a real-time suggestion produced during an encounter is generated somewhere.

The named integrations are the largest hospital record systems in the United States. A buyer of that size will have a residency position of its own and a subprocessor review process, so this gap is likely to be closed in contracting rather than in published material. That does not help a buyer comparing vendors before a sales conversation.

Commercial
CC on Commercial TransparencyNo price is published and the posture is discoverable: a buyer can establish how the product is sold and what drives the cost before contacting the vendor. Most of the index sits here.
Vendor Published

No price, unit of pricing, tier structure or trial is published, and no third party estimate appears either. The routes in are a demo request and marketplace listings, neither of which exposes a rate.

BB on Setting and Specialty CoverageCoverage is named with validation behind part of it.
Vendor Published

More than 15 specialties with specialty-specific templates, spanning ambulatory practice and hospital or health system settings.

The output range is wider than the specialty count suggests and is the real distinguishing feature: SOAP notes, pre-charting before the visit, after-visit summaries, and referral letters to other specialties, which is a document type many scribes never produce at all. Pre-charting and referral generation both sit outside the encounter itself, so the product covers more of the documentation day than a capture-and-write tool.

The after-visit summary is the standout. It is generated with education materials, treatment regimens and caregiver notes tailored to the patient's health literacy level and preferred language, which reaches the caregiver as a reader rather than only the clinician and the payer. Most documentation products treat the after-visit summary as a formatting step; treating it as a comprehension problem is a different design decision and a better one.

Two things fall short. The specialty count is modest and, more importantly, no specialty instrument is named anywhere: templates are described by specialty label rather than by the scores, staging systems or measures that specialty actually records, which is the difference between a template library and domain depth. And no deployment is named in any setting, so the ambulatory and hospital claims are both unevidenced.

Alternatives

Alternatives to Reteta

Vendors in the same categories as Reteta whose graded profiles look most alike, with a line on what each product does.

Similar is not the same, so check that each one does the job you need. No vendor pays for placement.

Ambient scribe built for home health field clinicians and structured entirely around the OASIS, the federally mandated assessment instrument that drives both quality reporting and episode…

Apricot, based in Oklahoma City, builds AI documentation for home health and post acute care.

QiiQ Healthcare, pronounced quick, is a Vancouver company whose scribe is built specifically for the emergency department rather than adapted to it.

AvodahMed is the digital health division of Avodah, Inc., a Texas company whose other division builds language translation technology, and that lineage explains the multilingual capture at…

CareCortex is the clinical documentation platform from NeuroReef Labs, a Mountain View company that also builds MedAura, a separate evidence retrieval product that appraises evidence with…

Enzo Health builds AI documentation for home health, and describes itself as an AI native home health EHR that replaces the legacy system and the point solutions running on it, covering…

Ordered by how closely the graded profiles match across the fifteen axes, inside the same categories. See how each axis is graded in the methodology.

Comparisons

Compared With

Each comparison carries a written verdict, the buyer conditions that favor each vendor, and a graded side by side. Pairs that cross a category boundary are grouped separately, and their verdicts state where the boundary sits rather than manufacturing a head to head.

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
Not published. Access is by demo request, with listings on the Elion and AVIA marketplaces.
Not disclosed. Two products are sold, Reteta sKribe for documentation and Reteta Bcoder for coding, and whether they are licensed together or separately is not stated. States HIPAA ONE certification, naming an actual third party compliance program. BAA terms and availability not published. None published. Positioned as bolting onto an existing EHR over secure APIs without disrupting existing infrastructure, which implies no migration project, though integration scoping for a specific EHR is not addressed. Vendor Published

Four questions worth asking, and the first is the one this index most wants answered. Ask for the accent and dialect accuracy work behind the 86 percent figure: the cohort, the accents tested, the reference standard and the error definition. Reteta is the only ambient vendor found publishing an accent broken out number, so if that work is real it is a category leading disclosure and should be demanded in full; if it is an estimate, that matters too.

Second, ask which of the four published accuracy figures applies to what, since 86 percent across accents, up to 95 percent overall, 80 percent of notes accepted unedited and 90 percent coding accuracy cannot all be describing the same measurement. Third, ask for the HIPAA ONE certification date and scope.

Fourth, establish whether EHR write back lands as discrete coded fields or as pasted text, since the product is described as bolting onto any EHR and universality in this lane usually indicates a shallower mechanism than the standards language implies. The company is small, roughly one to ten people on $2 million of seed funding, so supplier continuity belongs in the diligence alongside the product.